Tuesday, November 17, 2015
Takara Bio Europe AB, a wholly-owned subsidiary of Takara Bio Inc., announced today that it is launching the Cellartis® iPS Cell to Hepatocyte Differentiation System and related ancillary products. This system provides a complete solution for directed differentiation of disease-specific or patient-specific human inducible pluripotent stem (hiPS) cells to hepatocytes by combining a standardized protocol and optimized, ready-to-use media and coating reagents.
Takara Bio Europe AB has been offering human iPS cell-derived hepatocytes, Cellartis Enhanced hiPS-HEP cells, since 2010. These cells are a highly homogeneous population of hepatocytes derived from hiPS cells. Now for the first time, Takara Bio Europe AB's proven hepatocyte differentiation protocol will be available in a do-it-yourself kit format, enabling researchers to differentiate their own hiPS cells into definitive endoderm and further into hepatocytes using a highly robust and reproducible workflow. The hepatocyte differentiation workflow was developed by Takara Bio Europe AB scientists following extensive internal testing and validation on more than 25 lines, including three commercially available hiPS cell-derived hepatocyte products prepared from different donors.
"This novel differentiation system is the first commercially available product to support the complete differentiation workflow from hiPS cells to definitive endoderm and further to hepatocytes," said Kristina Runeberg, Site Head and Senior Director, Business Development, at Takara Bio Europe AB. "We're excited to expand our product offering with a complete hepatocyte differentiation system that can allow the creation of large panels of hiPSC-derived hepatocytes with specific genotypes/phenotypes, providing an ideal solution for disease modeling, in vitro drug discovery, drug metabolism, and toxicology-related studies."
prnewswire.com
